89bio, Inc. Banner Image

89bio, Inc. has reached its limit for free report views

Work for 89bio, Inc.? Upgrade Your Profile and unlock all your annual reports.

89bio, Inc.

  • Ticker ETNB
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
89bio, Inc. Logo Image
  • 11-50 Employees
  • Based in San Francisco, California
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is being developed for the treatment of NASH and for the treatment of SHTG. BIO89-100 is a specifically engineered glycoPEGylated analog of FGF21 that is currentlyMore in a proof of concept Phase 1b/2a clinical trial in patients with NASH or NAFLD and a high risk of NASH and a Phase 2 trial in patients with SHTG is expected to initiate shortly. 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
89bio, Inc.

Most Recent Annual Report

89bio, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. 89bio, Inc. has reached its limit for free report views.

Older/Archived Annual Reports